Di Lauro L, Fattoruso Au moment ou, Giacinti L, ainsi que al. Second-line chemo that have FOLFIRI in the patients with metastatic gastric malignant tumors (MGC) maybe not previously given fluoropyrimidines. J Clin Oncol. 2009. s (suppl; abstr 4549).

Burtness B, Gibson Yards, Egleston B, mais aussi al. Phase II demonstration away from docetaxel-irinotecan consolidation inside complex esophageal malignant tumors. Ann Oncol. 2009 Jul. 20(7):1242-8. [QxMD MEDLINE Connect].

A phase II demonstration evaluating capecitabine and you can irinotecan as second-line medication inside clients with oesophago-gastric cancer who have evolved into the, otherwise within ninety days of rare metal-centered radiation treatment

Catenacci DVT, Kang YK, Park H, et al. Margetuximab and additionally pembrolizumab during the people having previously managed, HER2-confident gastro-oesophageal adenocarcinoma (CP-MGAH22-05): one-sleeve, phase 1b-dos demonstration. Lancet Oncol. 2020 Aug. 21 (8):1066-1076. [QxMD MEDLINE Link]. [Full Text message].

Doebele Rc, Drilon A, Paz-Ares L, Siena S, et al. Entrectinib in the people having state-of-the-art otherwise metastatic NTRK mix-self-confident strong tumours: integrated investigation regarding three phase step 1-dos trials. Lancet Oncol. 2020 Feb. 21 (2):271-282. [QxMD MEDLINE Link]. [Complete Text].

Drilon An excellent, Laetsch TW, Kummar S, DuBois SG, mais aussi al. Efficacy of Larotrectinib inside TRK Combination-Self-confident Cancer from inside the People and children. N Engl J Med. 2018 Feb 22. 378 (8):731-739. [QxMD MEDLINE Connect]. [Full Text message].

Ce DT, Durham JN, Smith KN, et al. Mismatch repair lack forecasts impulse out-of good cancers so you’re able to PD-step one blockade. Science. 2017 Jul twenty-eight. 357 (6349):409-413. [QxMD MEDLINE Hook up].

Ce DT, Uram JN, Wang H, et al. PD-step one Blockade for the Cancers having Mismatch-Fix Insufficiency. Letter Engl J Med. 2015 Jun twenty-five. 372 (26):2509-20. [QxMD MEDLINE Hook up].

You. Sahin, O

Tabernero J, Yoshino T, Cohn AL, Obermanucirumab in place of placebo in combination with next-line FOLFIRI inside clients having metastatic colorectal carcinoma you to progressed throughout otherwise immediately after basic-line procedures with bevacizumab, oxaliplatin, and you may an excellent fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase step 3 research. Lancet Oncol. 2015 Will get. 16 (5):499-508. [QxMD MEDLINE Connect]. [Full Text message].

Mitani S, Kadowaki S, Komori An excellent, Kondoh C, Oze I, Kato K, et al. A stage II Study of Changed FOLFOX6 getting State-of-the-art Gastric Cancer tumors Refractory in order to Simple Treatments. Adv Ther. 2020 Jun. 37 (6):2853-2864. [QxMD MEDLINE Connect]. [Full Text].

Shitara K, Doi T, Dvorkin Yards, Mansoor W, Arkenau HT, Prokharau An effective, mais aussi al. Trifluridine/tipiracil instead of placebo in clients that have heavily pretreated https://datingmentor.org/pl/muzulmanskie-randki/ metastatic gastric cancer tumors (TAGS): a randomised, double-blind, placebo-regulated, phase step three demonstration. Lancet Oncol. 2018 Late. 19 (11):1437-1448. [QxMD MEDLINE Hook].

Kawazoe An excellent, Ando T, Hosaka H, Fujita J, Koeda K, Nishikawa K, ainsi que al. Defense and you will craft regarding trifluridine/tipiracil and you may ramucirumab when you look at the prior to now treated advanced gastric cancer tumors: an open-name, single-case, phase dos demonstration. Lancet Gastroenterol Hepatol. 2021 Mar. 6 (3):209-217. [QxMD MEDLINE Hook up]. [Complete Text message].

Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, ainsi que al. A level step 3 study of nivolumab inside the prior to now addressed state-of-the-art gastric or gastroesophageal junction cancer tumors (ATTRACTION-2): 2-year change research. Gastric Disease. 2020 Get. 23 (3):510-519. [QxMD MEDLINE Hook]. [Complete Text message].

Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe An excellent, Asayama Meters, mais aussi al. Regorafenib In addition to Nivolumab inside the People With Cutting-edge Gastric otherwise Colorectal Cancer: An open-Name, Dose-Escalation, and you will Dose-Extension Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020 Jun 20. 38 (18):2053-2061. [QxMD MEDLINE Connect]. [Full Text].

Tureci, Grams. Manikhas, mais aussi. al. FAST: a great randomised stage II examination of zolbetuximab (IMAB362) and additionally EOX rather than EOX alone to have basic-line remedy for advanced CLDN18.2-positive gatric and you will gastro-oesophageal adenocarcinoma. Annals regarding Oncology. 2021 Can get. Vol -619. [Full Text message].

Nivolumab prolonged situation 100 % free emergency inside the people having resected (R0) stage II otherwise III esophageal otherwise gastroesophageal junction malignant tumors exactly who received neoadjuvant chemoradiotherapy together with recurring pathological state.

Docetaxel 70-85 milligrams/meters dos IV for the go out step 1 plus cisplatin 70-75 milligrams/yards 2 IV towards date 1; most of the 21 d [forty-five, 46, 47] or

Javle MM, Yang G, Nwogu Le, et al. Capecitabine, oxaliplatin and radiotherapy: a level IB neoadjuvant data to have esophageal malignant tumors that have gene expression study. Disease Purchase. 2009 Feb. 27(2):193-200. [QxMD MEDLINE Connect].

Enzinger Desktop computer, Burtness BA, Niedzwiecki D, Ye X, et al. CALGB 80403 (Alliance)/E1206: An excellent Randomized Stage II Examination of About three Chemo Regimens Also Cetuximab within the Metastatic Esophageal and you can Gastroesophageal Aug ten. 34 (23):2736-42. [QxMD MEDLINE Hook]. [Complete Text].

Albertsson Yards, Johansson B, Friesland S, et al. Phase II knowledge with the docetaxel alone all 3rd month, or each week in conjunction with gemcitabine inside clients that have number one in your community complex, metastatic, or perennial esophageal cancer tumors. Med Oncol. 2007. 24(4):407-12. [QxMD MEDLINE Hook].

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua Roentgen, Goswami C, et al. Ramucirumab monotherapy to own in earlier times managed complex gastric or gastro-oesophageal junction adenocarcinoma (REGARD): a worldwide, randomised, multicentre, placebo-regulated, stage step three demonstration. Lancet. 2014 The month of january cuatro. 383(ninenine11):31-nine. [QxMD MEDLINE Hook].